Last updated: February 17, 2026
What is NDC 00065-8150?
The National Drug Code (NDC) 00065-8150 corresponds to Doxorubicin Hydrochloride Injection, a chemotherapy agent used primarily for treating different types of cancers, including breast, bladder, and ovarian cancers. It is marketed under various brand names, such as Adriamycin.
Market Overview
Size and Growth
- The global oncology drug market was valued at approximately $180 billion in 2022, with chemotherapeutic agents representing roughly 25% of this market (source: IQVIA).
- Doxorubicin's sales accounted for about 7% of chemotherapy drug sales in the U.S. market in 2022, with outpatient administration being dominant.
- The market saw a compounded annual growth rate (CAGR) of around 4% from 2018 to 2022, driven primarily by rising cancer prevalence, aging populations, and increased adoption of chemotherapy regimens.
Competitive Landscape
- Brand vs. Generic: Adriamycin remains the most recognized brand, but generic versions, including the one identified by this NDC, have gained market share following patent expirations (patent expired in 2000).
- Major competitors include Pfizer, Amgen, and Sandoz, with generic manufacturers holding approximately 75% of the market share.
Regulatory Environment
- Strict FDA regulations govern the manufacturing and distribution of cytotoxic drugs.
- The biosimilar and generic landscape is evolving, with some companies seeking abbreviated pathways for oncology drugs under biosimilar regulations.
Pricing Dynamics
Historical Pricing Trends
- The average wholesale price (AWP) for Doxorubicin injection ranged from $12 to $18 per vial (depending on dosage), as of 2022.
- Generic versions saw a significant price reduction after market entry, with prices declining by approximately 30–50% within the first year.
- Actual transaction prices for hospitals and pharmacies are often 30–40% lower than AWP, influenced by negotiations and discounts.
Current Price Estimates
| Dose (mg) |
Wholesale Price per Vial |
Range (USD) |
Notes |
| 10 mg |
$10 - $15 |
$12.50 |
Commonly used for low-dose scenarios |
| 50 mg |
$50 - $75 |
$62.50 |
Standard high-dose vial |
| 100 mg |
$100 - $150 |
$125 |
Larger vial, less common |
Note: Prices fluctuate based on supply chain factors, insurance negotiations, and geographic region.
Market Trends and Future Projections
- Biosimilars and Generics: Increased competition from biosimilars could push prices downward further over the next 3–5 years.
- Regulatory Changes: Any new guidelines on biosimilar substitution or price transparency could impact market pricing.
- Patent Status: As a generic, patent expiry facilitates market saturation, which limits pricing power.
- Market Penetration: Use of doxorubicin is expected to decline slightly as newer targeted therapies and immunotherapies gain prominence, but remains a mainstay in chemotherapy protocols.
Price Projection Outlook (2023–2028)
| Year |
Estimated Average Price per Vial (USD) |
Comments |
| 2023 |
$12 - $16 |
Stable with minor fluctuations |
| 2024 |
$11.50 - $15.50 |
Slight downward pressure from increasing biosimilar presence |
| 2025 |
$11 - $15 |
Continued generic competition |
| 2026 |
$10.50 - $14.50 |
Price stabilization expected amid new biosimilar entries |
| 2027 |
$10 - $14 |
Market saturation limits significant declines |
| 2028 |
$9.50 - $13.50 |
Potential further reduction due to supply chain adjustments |
Key factors influencing prices include shifts in payer negotiations, supply chain efficiencies, formulations, and regional market variations.
Key Takeaways
- NDC 00065-8150 corresponds to generic doxorubicin hydrochloride injection.
- The overall market is declining in price due to increased biosimilar and generic competition.
- Prices range between $10 and $15 per 10 mg vial, with larger doses proportionally more expensive.
- Revenue in the chemotherapy drug market remains substantial, though it faces pressure from new therapies.
- The trend toward biosimilar adoption will likely stabilize prices and limit future growth potential.
FAQs
1. How does the price of generic doxorubicin compare to the branded version?
Generic doxorubicin typically costs 20–50% less than the branded counterpart due to patent expiration and increased competition.
2. Will the price of doxorubicin increase or decrease in the future?
Prices are expected to decline gradually over the next five years, influenced by biosimilar entry and market saturation.
3. What are the primary factors affecting pricing power?
Market competition, regulatory policies, supply chain costs, and payer negotiations primarily influence prices.
4. Is there a significant difference in efficacy between generic and brand-name doxorubicin?
No. FDA approval standards ensure bioequivalence and clinical effectiveness are comparable.
5. What regions show higher or lower prices for this drug?
Prices tend to be higher in the US due to pricing regulation differences and negotiations. International prices are generally lower, affected by local healthcare policies and manufacturing costs.
Sources
- IQVIA Institute, "The Global Oncology Market," 2022.
- FDA, "Doxorubicin Hydrochloride Injection," 2021.
- Drugs.com, "Doxorubicin Prices," 2023.
- Medicare and Medicaid Drug Pricing Data, 2022.
- Health Affairs, "Biosimilars and Generic Oncology Drugs," 2021.
